Innovation

Diagnostic Methods for Detecting Congenital Bone Defects

University of Missouri System: University of Missouri-Kansas City
posted on 03/12/2010

Methods for screening patients for autosomal recessive hypophosphatemic rickets (ARHR) resulting from defective Dentin Matrix Protein 1 (DMP1) expression.

Suggested Uses

  • The methods described are useful to test the expression of an additional gene that should be screened to detect ARHR individuals.
  • Research for the treatment of osteoporosis and other bone disease.
  • Advantages

    Identifies ARHR individuals who would not previously have been identified by existing tests.

    Innovation Details
     

    Detailed Description

    Invention Details:

    This innovation is related to methods for screening patients for autosomal recessive hypophosphatemic rickets (ARHR) resulting from defective Dentin Matrix Protein 1 (DMP1) expression. These methods are used to genetically screen patients for the presence of defects in the (DMP1) to diagnose the existence of, or assess the risk of producing offspring from those who suffer from ARHR.

    One method relates to detecting individuals that express a defective DMP1 protein. Such individuals may exhibit ARHR or they may be carriers of the disease. This method involves sequencing either a portion of, or the entire length of the DMP1 gene isolated from the individual undergoing analysis to identify DMP1 variants. More particularly, the patient's DMP1 sequences are screened to detect a DMP1 variant that has a deletion of nucleic acid sequences 1484-1490 (deletion of CTATCAC; SEQ ID NO: 35) and the presence of the contiguous sequence CCAACTGTGAAGATC (SEQ ID NO: 36).

    A second testing method utilizes a kit for screening biological samples for the presence of defective DMP1 genes. The kit is comprised of a set of PCR primers for amplifying the DMP1 gene, or alternatively the kit has one or more sets of PCR primers for amplifying one or more specific regions of the DMP1 gene. The kit may be further provided with reagents for conducting nucleic acid sequencing, one or more reagents for conducting PCR reactions, or labeled nucleic acid probes that specifically bind to defective DMP1 gene sequences relative to the native DMP1 sequence.

    Another method described by this technology would detect aberrant DMP1 expression in a patient's cells, as a diagnostic indicator of ARHR. The method comprises contacting proteins of the patient's tissue with an ligand that specifically binds to the peptide of SEQ ID NO: 42 or SEQ ID NO: 43, detecting specific ligand-DMPl complexes, wherein the formation of ligand-DMP1 complexes indicates a risk of developing ARHR.

    File Number: 07UMK097 

    Disease: Musculoskeletal Disorders


    IP Protection


    License Online

    This innovation currently is not available for online licensing. Please contact James Brazeal at University of Missouri System: University of Missouri-Kansas City for more information.

    Request more info via email request more info
    People

    Principal Investigator:

    Lynda  Bonewald Lynda Bonewald

    Innovations (3)

    Publications (3)


    Case Manager:

    James Brazeal James Brazeal

    Innovations (12)


    Download Technology Brief (PDF)


    Followed By

    Follow this innovation



    No one is following this innovation.

    Organization
    Profile
    Related Tags

    Find more innovations


    February 11, 2009

    8,815 members 16,688 innovations 159 organizations

    Browse

    Dr. Jörg Knäblein – Technology Scouting, Bayer Schering Pharma AG

    "Through the iBridge Network, I was able to find a mouse model I was looking for. The collaboration available through the iBridge Network is crucial in driving innovation and I'll continue using it as a valued resource."  read more...